← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Zata Pharmaceuticals, Inc.
Worcester, MA
$6,231,294
Total funding
6
Grants
Funding over time
peak $1.9M · FY2014–21$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$6,231,294 · 6
By mechanism
R44$4,345,041 · 2
R43$1,886,253 · 4
Investigators at Zata Pharmaceuticals, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
A CLOSED SYSTEM FOR PATHOGEN REDUCTION OF RED BLOOD CELLS FOR TRANSFUSION$1,169,287
R44 · FY2021 · HL
A CLOSED SYSTEM FOR PATHOGEN REDUCTION OF RED BLOOD CELLS FOR TRANSFUSION$1,010,910
R44 · FY2020 · HL
SELF-NEUTRALIZING OLIGONUCLEOTIDES WITH ENHANCED CELLULAR UPTAKE$796,420
R44 · FY2016 · GM
A CLOSED SYSTEM FOR PATHOGEN REDUCTION OF RED BLOOD CELLS FOR TRANSFUSION$780,492
R44 · FY2019 · HL
Highly Selective Pathogen Inactivators For Treatment of Convalescent Transfusion Plasma$717,598
R43 · FY2021 · HL
SELF-NEUTRALIZING OLIGONUCLEOTIDES WITH ENHANCED CELLULAR UPTAKE$587,932
R44 · FY2017 · GM
AZIRIDINYL GROUPS CONTAINING POLYAMINES AS ANTI-PATHOGEN DEVICE FOR BLOOD PRODUCTS INTENDED FOR TRANSFUSION$402,588
R43 · FY2015 · HL
New-Generation of Fluorescently-Labeled Charge-Neutralized Oligonucleotides as Probes for the Detection and Quantification of MicroRNAs and Oligonucleotide-Based Therapeutics in Biological Samples$402,225
R43 · FY2018 · GM
SELF-NEUTRALIZING OLIGONUCLEOTIDES WITH ENHANCED CELLULAR UPTAKE$363,842
R43 · FY2014 · GM